Dialog Box

Results of the CheckMate 743 trial published

Mesothelioma is a rare cancer that affects the lining of the lungs and other internal organs. 

The CheckMate 743 phase III clinical study evaluated the effectiveness of the combination of nivolumab and ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma. The findings suggest that treatment with nivolumab and ipilimumab significantly prolonged overall survival rate compared to that of chemotherapy, thereby supporting its use as first-line therapy for patients suffering from this deadly disease.

Read full article 

22 April 2022
Category: News